ClinicalTrials.gg
RecruitingNCT07721961Updated Jul 23, 2026

A Study of MI078 for Postpartum Depression

A Phase 3 interventional study of MI078 capsule and Placebo of MI078 capsules in Postpartum Depression (PPD), sponsored by Nanjing Minova Pharmaceutical Co., Ltd.. Recruiting at 36 sites in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Nanjing Minova Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Depression, Postpartum with a site in China — 9 open to participants now, 10 under way, 1 of them phase 3. Depression, Postpartum · China.

Planned enrollment
11th of 17
200 · median 270
Started
2026
with 4 others
Phase 3
Only one
of the 20
Registered
19th of 20
by date
Lead sponsor
3 of 20
Nanjing Minova Pharmaceutical Co., Ltd.

Among the 20 studies in Depression, Postpartum with a site in China, this one is the 11th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 3, and was the 19th registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

9 of the 20 studies in Depression, Postpartum with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Depression, Postpartum with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled trial consisting of an experimental drug group and a placebo group, each enrolling 100 participants. The objective of this study is to assess the efficacy and safety of MI078 capsules for the treatment of postpartum depression.

Read the detailed description

This study is designed as a multicenter, randomized, double-blind, placebo-controlled parallel-group trial. It plans to enroll two groups - one receiving the investigational drug and the other receiving placebo - with 100 participants per group. The study includes a screening period (Day -14 to Day -1), a treatment period (Days 1 to 4), and a follow-up period (Days 5 to 31). Eligible participants will be randomized in a 1:1 ratio and will take the study drug for a total of 3 days.

03

Conditions studied

  • Postpartum Depression (PPD)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients aged 18-45 years (inclusive) with a (BMI) of 18.5-37.0 kg/m² (inclusive).
  • Based on the investigator's clinical evaluation, the participant meets the diagnostic criteria for Major Depressive Disorder (MDD) according to the , Fifth Edition (DSM-5), confirmed by clinical assessment and the Mini-International Neuropsychiatric Interview (M.I.N.I.), with onset of depression between gestational week 28 and 4 weeks postpartum (inclusive).
  • Within 12 months postpartum at baseline.
  • Total score ≥26 on the 17-item Hamilton Depression Rating Scale (HAM-D17) at both screening and baseline.
  • Understand and voluntarily participate in this trial, agree to comply with all study requirements, and provide written prior to any study-specific procedures.
  • Able to communicate well with the investigator, willing and able to comply with lifestyle restrictions or requirements specified in the protocol, and capable of completing the trial as required.

Exclusion criteria

Exclusion Criteria:

  • Currently meeting diagnostic criteria for other psychiatric disorders, as assessed by the investigator.
  • History of bipolar disorder, schizophrenia, and/or schizoaffective disorder.
  • Reduction in HAM-D17 total score from screening to baseline ≥25%.
  • Presence of suicidal ideation/intent, or HAM-D17 Item 3 (suicide) score >3, or a "yes" response to Item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) for suicidal ideation in the past 6 months at baseline, or a history of suicidal behavior within 1 year.
  • Meeting diagnostic criteria for treatment-resistant depression.
  • Continuous use of therapeutic doses of antidepressants for more than 14 days during the current episode.
  • Discontinuation of psychotropic medications for less than 5 half-lives prior to the first dose of study drug.
  • Need for concomitant use of other psychoactive drugs during the treatment period, including antidepressants, antipsychotics, mood stabilizers, and sedative-hypnotics (excluding non-benzodiazepines).
  • Discontinuation of strong inducers or inhibitors for less than 5 half-lives prior to the first dose of study drug.
  • Receipt of systematic psychotherapy (e.g., interpersonal therapy, psychodynamic therapy, cognitive-behavioral therapy) or psychiatric-related acupuncture within 1 week prior to the first dose, or planned receipt of such treatments during the trial.
  • Receipt of other physical treatments for psychiatric disorders (e.g., modified electroconvulsive therapy, transcranial magnetic stimulation, psychiatric-related laser therapy, vagus nerve stimulation, deep brain stimulation, light therapy) within 1 month prior to screening.
  • Presence of severe or unstable cardiovascular, hepatic, renal, hematological, endocrine (e.g., uncontrolled hyper- or hypothyroidism), neurological (e.g., epilepsy, Parkinson's disease, multiple sclerosis, Huntington's disease, history of seizure disorder [except single febrile seizure in childhood]), gastrointestinal (e.g., history of gastrointestinal disease or surgery that may interfere with drug absorption, distribution, metabolism, or excretion), or other systemic or organ diseases, as judged by the investigator.
  • History of within 1 year prior to screening.
  • Participation in another drug trial within 3 months prior to screening, or participation in a medical device trial within 1 month prior to screening (defined as having received drug or device treatment).
  • Major surgery (excluding cesarean section) within 1 month prior to screening, or planned surgery during the trial period.
  • History of (allergy to at least 2 substances) or known allergy to progesterone.
  • Positive pregnancy test at screening or baseline (for participants who are 4 weeks postpartum, a positive result requires retesting), or unwillingness to use effective throughout the trial and for at least 3 months after the last dose of study drug, or plans for oocyte donation during this period.
  • abnormal 12-lead (ECG) or laboratory findings at screening or baseline that, in the investigator's opinion, may affect the trial, including but not limited to (ALT) or aspartate aminotransferase (AST) >2× (ULN), or serum creatinine >1.5× ULN.
  • Currently breastfeeding and unwilling to discontinue breastfeeding during the treatment period and for 7 days after the last dose.
  • Any physical/psychological illness or condition that, in the investigator's opinion, may increase the risk of the trial, affect compliance with the protocol, or interfere with the completion of the study, or any other condition that the investigator deems unsuitable for participation in this trial.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    MI078 capsule

    MI078 capsules

    Drug: MI078 capsule

  • Placebo comparator
    placebo

    Placebo of MI078 capsules

    Drug: Placebo of MI078 capsules

Interventions

  • MI078 capsule for 3 days

  • DrugPlacebo of MI078 capsules

    Placebo for 3days

06

What researchers measure

Primary outcomes

  1. Change from baseline in HAM-D17 total score

    The Seventeen-Item Hamilton Rating Scale for Depression (HAM-D17) contains 17 individual ratings related to the following symptoms: depressed mood, feelings of guilt, suicide, insomnia (initial, middle, and late), work and interests, psychomotor retardation, psychomotor agitation, anxiety (psychic and somatic), gastrointestinal symptoms, general somatic symptoms, sexual interest, hypochondriasis, insight, and weight loss. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: up to day 31

Secondary outcomes

  1. Change from baseline in the CGI-S score

    The CGI-S scale is a 7-point scale that requires the Investigator to assess how mentally ill is the patient at this time. 1 - normal, not at all ill; 2 - borderline mentally ill; 3 - mildly ill; 4 - moderately ill; 5 - markedly ill; 6 - severely ill; or 7 - among the most extremely ill patients

    Time frame: up to day 31

  2. HAM-D17 response

    Defined as having a 50% or greater reduction from baseline in HAM-D17 total score. The total score ranges from 0 to 52, with higher scores indicating more severe depression.

    Time frame: up to day 31

  3. HAM-D17 remission

    Defined as having a HAM-D17 total score ≤7. The total score ranges from 0 to 52, with higher scores indicating more severe depression

    Time frame: up to day 31

  4. Clinical Global Impression - Improvement (CGI-I) scale positive response

    The CGI-I scale is a 7-point scale that requires the Investigator to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of study drug treatment. 1 - very much improved; 2 - much improved; 3 - minimally improved; 4 - no change; 5 - minimally worse; 6 - much worse; or 7 - very much worse

    Time frame: up to day 31

  5. Change from baseline in MADRS total score

    The MADRS contains 10 individual items related to the following symptoms: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. The total score ranges from 0 to 60, with higher scores indicating more severe depression

    Time frame: up to day 31

  6. Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) total score

    The Edinburgh Postnatal Depression Scale (EPDS) is a set of 10 screening questions. The total score ranges from 0 to 30, with higher scores indicating more severe depression.

    Time frame: up to day 31

  7. Change from baseline in Hamilton Anxiety Rating Scale (HAM-A) total score

    The HAM-A contains 14 individual ratings related to the following symptoms: anxious mood, tension, fears, insomnia, intellectual, depressed mood, somatic (muscular), somatic (sensory), cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms, genitourinary symptoms, autonomic symptoms, and behavior at interview. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety.

    Time frame: up to day 31

Other outcomes

  1. Number of participants with treatment-emergent adverse events (TEAEs)

    Adverse events (AEs) will be assessed by type, frequency, severity, and relationship to study drug.

    Time frame: up to day 31

  2. Number of participants with Serious Adverse Events (SAEs)

    As defined by ICH-GCP guidelines

    Time frame: up to day 31

  3. Change from baseline in PR interval,QRS duration, QT interval and Fridericia-corrected QT interval (QTcF)

    The PR interval ,QRS duration, and QT interval will be measured from the 12-lead electrocardiogram (ECG) and reported in milliseconds (ms),The QT interval corrected for heart rate using Fridericia's formula (QTcF) will be derived from the 12-lead electrocardiogram (ECG) and reported in milliseconds (ms)

    Time frame: up to day 31

  4. Number of participants with suicidal ideation or behavior as assessed by C-SSRS

    The Columbia-Suicide Severity Rating Scale (C-SSRS) will be used to evaluate suicidal ideation and behavior

    Time frame: up to day 31

  5. Change from baseline in PWC-20 total score

    The PWC-20 scale will be used to evaluate the withdrawl reaction

    Time frame: up to day 31

  6. Number of participants with clinically significant laboratory abnormalities

    Clinical laboratory tests (including hematology, blood chemistry, and urinalysis) will be assessed. This outcome reports the count of participants with any clinically significant abnormality as judged by the investigator.

    Time frame: up to day 31

07

Study locations

36 of 36 sites recruiting
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui, China
    Recruiting
    • Feng Geng · Contact
  • Chongqing Three Gorges Hospital
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Shiyou Tang · Contact
  • The Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Lian Du · Contact
  • Xiamen Xianyue Hospital
    Xiamen, Fujian, China
    Recruiting
    • Yan Qiu · Contact
  • Gansu Provincial Hospital of Traditional Chinese Medicine
    Lanzhou, Gansu, China
    Recruiting
    • Shenghui Huang · Contact
  • The First Affiliated Hospital of Jinan University
    Guangzhou, Guangdong, China
    Recruiting
  • Zhaoqing Third People's Hospital
    Zhaoqing, Guangdong, China
    Recruiting
    • Guoqiang Cheng · Contact
  • Guangxi Zhuang Autonomous Region Brain Hospital
    Liuzhou, Guangxi, China
    Recruiting
    • Fang Fang · Contact
  • Guizhou Provincial People's Hospital
    Guiyang, Guizhou, China
    Recruiting
    • Hui Xiang · Contact
  • Affiliated Hospital of Zunyi Medical University
    Zunyi, Guizhou, China
    Recruiting
    • Guifang Chen · Contact
  • Hainan Anning Hospital
    Haikou, Hainan, China
    Recruiting
    • Yin Lin · Contact
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Cuixia An · Contact
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei, China
    Recruiting
    • Xiaona Sheng · Contact
  • Shiyan Taihe Hospital
    Shiyan, Hebei, China
    Recruiting
    • Chunqi Ai · Contact
  • Xingtai People's Hospital
    Xingtai, Hebei, China
    Recruiting
  • The Second Affiliated Hospital of Xinxiang Medical University (Henan Mental Health)
    Xinxiang, Henan, China
    Recruiting
    • Ruiling Zhang · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
    Recruiting
    • Yihui Hao · Contact
  • Zhengzhou Ninth People's Hospital
    Zhengzhou, Henan, China
    Recruiting
    • Xiaojuan Ma · Contact
  • Zhumadian Psychiatric Hospital
    Zhumadian, Henan, China
    Recruiting
    • Jingli Wang · Contact
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei, China
    Recruiting
    • Qirong Wan · Contact
  • Hunan Brain Hospital
    Changsha, Hunan, China
    Recruiting
    • Ning Yuan · Contact
    • Zhengyu Tang · Contact
  • Zhuzhou Third Hospital (Zhuzhou Psychiatric Hospital)
    Zhuzhou, Hunan, China
    Recruiting
    • Xiaoli Liu · Contact
  • Wuxi Mental Health Center
    Wuxi, Jiangsu, China
    Recruiting
    • Zhiqiang Wang · Contact
  • Xuzhou Dongfang Hospital
    Xuzhou, Jiangsu, China
    Recruiting
    • Shiping Xie · Contact
  • Ganzhou Third People's Hospital
    Ganzhou, Jiangxi, China
    Recruiting
    • Ying Shen · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Ailan Wan · Contact
  • Shandong Daizhuang Hospital
    Jining, Shandong, China
    Recruiting
    • Zengxun Liu · Contact
  • Linfen Central Hospital
    Linfen, Shanxi, China
    Recruiting
    • Dong Yan · Contact
  • Xi'an Mental Health Center
    Xi’an, Shanxi, China
    Recruiting
    • Huali Lin · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan, China
    Recruiting
    • Bo Zhou · Contact
  • The Affiliated Hospital of Southwest Medical University
    Luzhou, Sichuan, China
    Recruiting
    • Kezhi Liu · Contact
  • Huzhou Third People's Hospital
    Huzhou, Zhejiang, China
    Recruiting
    • Zhongxia Shen · Contact
  • Kangning Hospital Affiliated to Ningbo University
    Ningbo, Zhejiang, China
    Recruiting
  • The First Affiliated Hospital of Ningbo University
    Ningbo, Zhejiang, China
    Recruiting
    • Yunxin Ji · Contact
  • Beijing Anding Hospital, Capital Medical University
    Beijing, China
    Recruiting
    • gang Wang · Contact
  • Beijing Huilongguan Hospital
    Beijing, China
    Recruiting
    • Fude Yang · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Dec 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 23, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07721961
Lead sponsor
Nanjing Minova Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Jul 10, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

cuixia zhang
Contact
zhangcuixia@mnvpharma.com
025-86667819 ext. 833
gang Wang
principal investigator · Beijing Anding Hospital, Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MI078

Start the discussion